Answers are grounded in this paper and cite their sources.
Cohort study shows JAK inhibitors do not increase cardiovascular risk in alopecia areata patients, suggesting long-term use may be safe.
In a large, real-world cohort of 2,310 patients with severe alopecia areata, treatment with JAK inhibitors was not associated with increased risk of major adverse cardiovascular events or venous thromboembolism and was linked to lower cardiovascular risk compared to traditional immunosuppressants. These findings help address safety concerns and support JAK inhibitor's potential for long-term use in this population.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: